Next-generation chemotherapeutics represent a significant evolution in cancer treatment, aiming to overcome the limitations of traditional chemotherapy by enhancing precision, reducing toxicity, and improving therapeutic outcomes. While conventional chemotherapy indiscriminately targets rapidly dividing cells often harming healthy tissues next-gen approaches are designed to selectively attack cancer cells through more sophisticated mechanisms.

These novel therapies include targeted cytotoxics, antibody-drug conjugates (ADCs), and prodrug formulations that become activated specifically within the tumor microenvironment. Smart drug delivery systems, such as nanoparticles and biodegradable carriers, are also being utilized to deliver chemotherapeutic agents directly to tumor sites, minimizing systemic exposure and side effects.